State Street SPDR S&P Pharmaceuticals ETF
XPH
55 hedge funds and large institutions have $166M invested in State Street SPDR S&P Pharmaceuticals ETF in 2013 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 10 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 14
7% less funds holding
Funds holding: 59 → 55 (-4)
24% less capital invested
Capital invested by funds: $218M → $166M (-$51.9M)
28.41% less ownership
Funds ownership: 92.26% → 63.85% (-28%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFG
Pacific Financial Group
Bellevue,
Washington
|
+$4.92M |
| 2 |
LPL Financial
San Diego,
California
|
+$3.95M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$3.6M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$3.57M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$2.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$42M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$19.8M |
| 3 |
HF
Hoxton Financial
Shepherdstown,
West Virginia
|
-$7.79M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$7.52M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.98M |
XPH Hedge Fund Activity: Q3 2013 in Review
55 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q3 2013, worth a combined $166M — down 24% from $218M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of XPH and 6 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 23 added.
The largest buyer was Pacific Financial Group, opening a new position worth an estimated $4.92M. The largest seller was Fidelity Investments, exiting entirely with an estimated $42M sold.
- 55 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q3 2013, down from 59 in Q2 2013.
- Funds reported $166M of State Street SPDR S&P Pharmaceuticals ETF stock for Q3 2013, down 24% quarter-over-quarter.
- 6 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q3 2013 and 10 closed out, a net change of -4 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q3 2013 was Pacific Financial Group, an estimated $4.92M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q3 2013 was Fidelity Investments, an estimated $42M sold.
Based on aggregated 13F filings for Q3 2013.